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Abstract
Background: Endothelial cell antigens are important
targets in acute rejection (AR). Our goal was to meas-
ure the serum concentrations of pre-transplant anti-
endothelial cell antibody (AECA) in panel reactive
antibody (PRA) negative recipients and its impact on
AR within 6 months following renal transplantation.
Methods: We retrospectively examined pre-transplant
sera from 392 patients using cellular enzyme linked
immunosorbent assay (ELISA) with substrate from a
permanent endothelial cell line EAhy926. Equal vol-
umes of serum from 40 healthy volunteers were
mixed and used as the negative control.
Results: The positive rate of AECA was 15.8%. There
were no significant differences with respect to age,
gender, original disease, dialysis history, immune
suppressive regimen, cytomegalovirus (CMV) antigen
positive rate, complement dependent cytotoxicity
(CDC) level and soluble CD30 (sCD30) levels between
the AECA positive group and AECA negative group.
AR rate in the AECA positive group was higher than
that in the AECA negative group (35.5% vs. 22.4%,
ps0.023). The AECA positive patients had significant-
ly higher rates of acute grade II T-cell mediated rejec-
tion (TMR) and acute antibody mediated rejection
(AMR) compared with AECA negative patients. The
concentrations of sCD30, and AECA were independ-
ent risk factors for AR within 6 months; the odds
ratios were 7.005 and 2.469, respectively.
Conclusions: Positive AECA was an independent risk
factor for AR and appeared to correlate with relatively
severe rejection subtypes.
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Introduction
The vascular endothelium of transplanted organs is
the first line barrier between the allograft and the
host. It represents an important target for allograft-
directed immune responses (1). By expressing both
class I and class II human leukocyte antigens (HLA),
activated graft endothelium may become a target
for anti-HLA antibodies leading to acute or chronic
allograft rejection (2–4). Although it is clear that HLA
antigens expressed on activated graft endothelial
cells can become targets of the immune system, the
role of non-HLA antigens such as endothelial cell anti-
gens in renal transplantation have been proposed (5).
Anti-endothelial cell antibody (AECA) has been
found in a variety of autoimmune diseases, including
Wegener’s granulomatosis, rheumatoid vasculitis,
and scleroderma, with possible pathogenic contribu-
tions (6–8). It represents a heterogeneous group of
antibodies directed against a variety of antigenic
determinants on endothelial cells.
Following transplantation, the presence of antibod-
ies to non-HLA antigens has been reported to be a
target for transplant rejection (9, 10). Opelz reported
that an analysis of the clinical outcomes of 4084 HLA-
identical sibling transplantations, 10 years graft
survival was 72.4% for patients without anti-HLA anti-
bodies compared with 63.3% for patients with
1%–50% panel reactive antibodies (PRA), and 55.5%
for patients with PRA )50%. This may demonstrate
a role for non-HLA directed immune response (11).
Lucchiari et al. studied nine cases of irreversible vas-
cular rejection occurring in the absence of detectable
anti-HLA antibodies. In eight of nine eluates from kid-
neys with acute vascular rejection, they found the
presence of antibodies reacting with human umbilical
endothelial cells, but not with HLA antigens (12). In a
series of 80 consecutive patients undergoing cardiac
transplantation, Fredrich et al. reported significant
correlation between the occurrence of humoral rejec-
tion and the presence of AECA, as detected in a cell-
based enzyme linked immunosorbent assay (ELISA)
using human umbilical vein endothelial cells
(HUVECs) (13).
In this study, we retrospectively analyzed pre-trans-
plant serum AECA concentrations using an endothe-
lial cell-based ELISA in 392 cases of PRA negative
patients. Our goal was to determine the role of AECA
concentrations and its impact on the episodes of
acute rejection (AR) within 6 months following renal
allograft transplantation.
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Materials and methods
Patients’ population
The study protocol conformed to the provisions of the Dec-
laration of Helsinki and informed consents were obtained
from all the patients and volunteers. We collected blood
samples prior to transplantation from 392 renal allograft
recipients (272 males and 120 females) between December
1998 and August 2003. Patients undergoing a second trans-
plantation or with positive PRA were excluded. The average
age was 39.9 years (11–70 years). PRA was measured with
the lambda antigen tray (LAT) quantitative method by ELISA
(One Lambda, Canoga Park, CA, USA). A value of )10%
was defined as positive. The control group included 40
healthy volunteers (25 males and 15 females). Their sera was
AECA negative as tested by indirect immunofluorescence
using HUVEC as substrate (Euroimmun, Lübeck, Germany).
Equal volumes of serum from these 40 healthy volunteers
were mixed and used as negative control. All sera was
stored at –808C until tested.
Patient demographics including age, gender, original dis-
ease, history of dialysis, cytomegalovirus (CMV) antigen
positive rate, the levels of complement dependent cytotoxi-
city (CDC), HLA mismatch and pre-transplant serum soluble
CD30 (sCD30), and immune suppressive regimen and AR
episodes within 6 months post-transplantation were record-
ed. HLA typing was measured in A, B and DR loci using
polymerase chain reaction. The sCD30 concentration was
measured and classified according to previous work per-
formed in our laboratory (14). High sCD30 concentrations
were classified when measured values were )170 U/mL
while values less than this were considered to be low. Epi-
sodes of AR episodes were diagnosed by the clinical mani-
festations or allograft biopsy and classified into acute T-cell
mediated rejection (TMR) and acute antibody mediated
rejection (AMR) according to Banff 05 criteria (15). AMR
criteria were defined as positive peritubular capillary (PTC)
C4d staining by immunohistochemistry concomitant with
polymorphonuclear leukocyte infiltration in PTC and vascu-
litis or glomerulitis. Clinical rejection was diagnosed as acute
renal allograft dysfunction with no evidence of obstruction,
blood supply compromise or drug toxicity, without biopsy
and recovery following intensive immunosuppressive
therapy.
Cell culture and cellular ELISA
A cellular ELISA kit, prepared in our laboratory, was used for
detection of AECA. A permanent HUVEC line EAhy926 (16),
provided by Professor Edgell (University of North Carolina,
USA), was used as the substrate in the ELISA. The culture
medium consisted of a high glucose Dulbecco minimum
essential medium (DMEM) medium (GIBCO BRL, Gainthers-
burg, MD, USA) with 10% fetal bovine serum (FBS), 10
mmol/L glutamine. The cells were passaged at subcon-
fluence and dissociated with 0.25% typsin. After reaching
confluence following the 5th passage, cells were collected
and seeded into the wells (5=103 cells per well) of 96-well
cell culture plate (Costar, NY, USA). All the plates were pre-
pared simultaneously using the same passage of EAhy926
cells proliferated from one original cell.
The cellular ELISA kits were prepared as follows: after
seeding, the 96-well cell culture plates were incubated at
378C in 5% CO2 for 48 h until confluence, washed three times
with PBS-0.05% Tween, fixed at 48C for 10 min with PBS-
0.1% glutaraldehyde and blocked at 378C for 2 h with PBS-
2% bovine serum albumin (BSA). After allowing to dry, the
plates were stored at –208C. Cellular ELISA was performed
as follows: after washing twice with PBS-0.05% Tween,
patient sera (in duplicate) were added to wells at a dilution
of 1:50, incubated at 378C for 2 h. For each plate, there were
four wells for negative control serum and four wells for the
blank control (no serum added). Following two washes
with PBS-0.05% Tween, horseradish peroxidase-conjugated
mouse antihuman immunoglobulin (Dako, Glostrup, Den-
mark) was added to each well and incubated at 378C for an
hour. After washing three times and adding tetramethyl ben-
zidine, the plates were measured at 490 nm with an ELISA
reader (Bio-Rad, Hercules, CA, USA). The absorbance value
(A) was calculated as the average value of the wells for the
duplicate determinations for each sample. The AECA level
was calculated as P/N value. P/Ns(A patient–A blank control)/
(A negative control–A blank control).
Statistical analysis
Numerical results were reported as the mean"standard
deviation (SD). Differences between groups were compared
using the x2-test or one way analysis of variance. Multiva-
riate analysis with stepwise logistic regression was applied
to determine the risk of AR. These analyses were performed
with SPSS 13.0 software (SPSS Inc, Chicago, IL, USA). A
p-0.05 was considered to be statistically significant.
Results
AECA levels and clinical characteristics
The P/N value of pre-transplant sera was 1.32"0.34,
while the P/N value of sera from healthy controls
(negative control) was 1.02"0.29. A P/N value )1.60
(1.96 SD over the average value of negative control)
was considered to be AECA positive. There were 62
AECA positive patients out of all 392 patients (positive
rate 15.8%).
Clinical data for the AECA positive group and AECA
negative group are shown in Table 1. There were no
significant differences with respect to age, gender,
original disease, dialysis history, immune suppressive
regimen, CMV antigen positive rate, CDC and sCD30
concentrations between the AECA positive group and
the AECA negative group. The HLA-mismatch level
was higher in the AECA positive group compared with
the AECA negative group (5.4"0.7 vs. 4.6"1.0,
ps0.043).
Risk factors for AR
Ninety-six of 392 recipients developed AR within 6
months following transplantation. The AR rate in the
AECA positive group was higher than the AECA neg-
ative group (35.5% vs. 22.4%, ps0.023), as shown in
Table 2. With respect to AR subtypes, the AECA pos-
itive group had significant higher rates of grade II
TMR and AMR than patients in the AECA negative
group (see Table 2). There was no significant differ-
ence in the rate of clinical rejection between the two
groups.
The analysis of risk factors for AR (Table 3) indicat-
ed that the positive rates of AECA and CMV antigen,
and sCD30 concentrations in the AR group were sig-
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Table 1 Clinical characteristics in the AECA negative and the AECA positive recipients.
AECA AECA p-Value
negative positive
(330 cases) (62 cases)
P/N value 1.22"0.26 1.84"0.25
Age, years 39.7"11.4 40.8"11.4 0.474
Gender, male:female 228:102 44:18 0.448
Original disease 0.611
Chronic glomerulonephritis 298 57
Polycystic renal disease 9 4
Hypertensive nephropathy 3 0
Diabetic nephropathy 2 0
Lupus nephritis 5 0
Gouty nephropathy 5 0




HDF12 months 248 46
HD)12 months 18 8
PDF12 months 18 2




FK506 replaces CsA 9 1





CDC level 4.1"1.9 3.8"1.6 0.248
HLA mismatch 4.6"1.0 5.4"0.7 0.043
sCD30 level, U/mL 140.21"63.62 139.46"52.31 0.930
AECA, anti-endothelial cell antibody; HD, hemodialysis; PD, peritoneal dialysis; Pred, predinisolone; Aza, azathioprine; CsA,
cyclosporin A; MMF, mycophenolate mofetil; FK506, tacrolimus; CMV, cytomegalovirus; CDC, complement dependent cyto-
toxicity; HLA, human leukocyte antigens; sCD30, soluble CD30.
Table 2 Rates and types of acute renal allograft rejection in relation to the pre-transplant AECA concentration.
AECA AECA x2 p-Value
negative positive
(330 cases) (62 cases)
Acute rejection 74 (22.4%) 22 (35.5%) 4.814 0.023
Acute T-cell mediated rejection 39 (11.8%) 13 (21.0%) 4.520 0.032
Grade I 29 (8.8%) 7 (11.3%) 0.929 0.231
Grade II 10 (3.0%) 6 (9.7%) 6.948 0.019
Acute antibody mediated rejection 12 (3.6%) 6 (9.7%) 5.331 0.033
Clinical rejection 23 (7.0%) 3 (4.8%) 0.081 0.532
AECA, anti-endothelial cell antibody.
Table 3 Analysis of risk factors of acute rejection.
No acute rejection Acute rejection p-Value
(296 cases) (96 cases) (x2)
Age, years 40.5"11.7 37.9"10.1 0.046
Gender, male:female 206:90 66:30 0.485
AECA positive rate 13.5% (40/296) 22.9% (22/96) 0.023 (4.814)
CMV antigen positive rate 50.0% (96/192) 65.0% (52/80) 0.016 (5.122)
CDC level 4.0"1.8 4.3"2.0 0.201
HLA mismatch 4.8"1.0 4.5"0.8 0.343
sCD30 level, U/mL 129.29"55.75 173.39"68.14 -0.001
AECA, anti-endothelial cell antibody; CMV, cytomegalovirus; CDC, complement dependent cytotoxicity; HLA, human leukocyte
antigens; sCD30, soluble CD30.
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Table 4 Effects of other factors on acute rejection episodes
as estimated by stepwise logistic regression analysis.
Variable Odds ratio p-Value 95% CI
AECAa 2.469 0.010 1.236–4.932
sCD30b 7.005 -0.001 3.819–12.849
aAECA was considered as positive or negative; bsCD30 enter
into the equation with low or high level.
nificantly higher than those without AR. The average
age of patients in the AR group was lower than in
those without AR. The variables included in the mul-
tivariate analysis with stepwise logistic regression
were age, gender, AECA, CMV antigen, the degree of
HLA-mismatch, and CDC and sCD30. This confirmed
that sCD30 concentrations, and AECA positivity were
independent risk factors for AR within 6 months post-
transplant, with an odds ratio of 7.005 and 2.469,
respectively (Table 4).
Discussion
Mounting evidence suggests that antibodies targeting
vascular endothelial cell are involved in allograft
rejection (9, 10, 12, 13). However, the vascular endo-
thelial cell antigen system is a minor histocompati-
bility system, genetically linked to HLA antigens (1).
Some researchers have claimed that the number of
AECA positive sera tested by cellular ELISA decreased
dramatically when the sera were first incubated with
platelets to absorb anti-HLA antibodies (17). In the
present study, we only inspected pre-transplant, PRA
negative recipients to avoid cross reaction with anti-
HLA antibodies. We found the positive rate of AECA
in this population to be 15.8%. The AR rate in the
AECA positive group was 35.5% higher compared
with the AECA negative group. The positive AECA
level was confirmed to be an independent risk factor
for AR, with a 95% confidence interval (CI) of
1.236–4.932. It appeared to correlate with relatively
severe rejection subtypes, such as grade II TMR and
AMR. Researchers at another Chinese center also
reported three renal allograft recipients who devel-
oped C4d-positive AR with detectable circulating
AECA (18). These patients had severe dialysis-
dependent graft dysfunction and two patients lost
their grafts following rescue therapy; one had an
AECA titer increase from 1:10 to 1:80, while the other
remained AECA positive during treatment. However,
in the patient that recovered, the AECA titer decreased
to become undetectable from an initial titer of 1:40.
They also analyzed circulating AECA concentrations
in 653 renal recipients and found that circulating
AECA was positive in 13 of 47 cases with acute vas-
cular rejection. These were mostly resistant to steroid
treatment and were associated with a significantly
lower 1-year graft survival rate. More patients with
AECA positive acute vascular rejection experienced
one or more episodes of AR during the 1 year of
follow-up (19).
AECA concentrations may rise secondary to pre-
existing endothelial injury or viral infection. Toyoda
et al. claimed that CMV infection was associated with
increased humoral immune response to endothelial
cell antigens (20), and it could induce polyclonal
AECA which recognize endothelial cell antigens and
antigens on other cells (21). In our study, the CMV
antigen positive rate in AECA positive patients (63%)
was higher compared with AECA negative patients
(52%), but this was not statistically different
(ps0.096). This may be due to the exclusion of PRA
positive patients and sample size.
It is now clear that vascular endothelial cells are
heterogeneous, include macro- and microvasculature,
exhibit tissue-specific differences and different patho-
genic significance (22). There are differences in anti-
gen composition and reactions to stimuli between the
endothelium from large and small vessels, and
between endothelial cells derived from various micro-
vascular endothelial beds (23). The EAhy926 cell line
was derived by fusing HUVECs with a permanent
human epithelial cell line A549 (16). In a retrospective
assay, a cell-based ELISA using A549 cell line did not
show any relationship between the presence of anti-
bodies against A549 and renal allograft rejection or
transplant failure (24). Endothelial cell antigens may
explain the positive relationship between positive
AECA concentrations and AR episodes in this study.
However, in a study using cellular ELISA with target
cells of HUVEC, human glomerular endothelial cells
(HGEC) or microvascular endothelial cells (MvEs)
from 22 renal transplant recipients, only the AECA
concentration measured with the HGEC based ELISA
showed significant correlation with AR episodes with-
in 3 months following transplantation (25). These
results appear contradictory with ours and may be
caused by the different numbers of patients prepara-
tion of the ELISA. Although cellular ELISA is conven-
ient for testing multiple samples, results are affected
by antigen loss between cell generations and uneven
distributions in cell proliferation. In this study, we
used the same fifth passage of EAhy926 cells prolif-
erated from one original cell to make all of our ELISA
plates at the same time, in order to avoid differences
between generations. Before testing, we use negative
control serum and five patients sera samples to eval-
uate the intra-plate deviation (each serum tested ran-
domly in eight wells in one plate). The average
deviation was 4.89%. During testing, we also used
the negative control and blank control to evaluate
deviation between different plates. The average devi-
ation was 8.87%. With these results, we concluded
that this cellular ELISA using EAhy926 was a reliable
method to measure AECA concentrations. However,
further experimental validation is required at other
centers.
In conclusion, antibodies against endothelial cells
may exist in pre-transplant PRA negative sera. A pos-
itive AECA level was found to be one of the risk
factors for AR within 6 months following transplan-
tation and appeared to correlate with relatively severe
rejection subtypes.
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